Top

Cardiovascular Diabetology

Published in:

Open Access 01-12-2024 | Diabetes | Research

Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials

Authors: Xiaolei Sun, Cheng Zhang, Yarong Ma, Yanzheng He, Xiaodong Zhang, Jianbo Wu

Published in: Cardiovascular Diabetology | Issue 1/2024

Abstract

Importance

Diabetes mellitus (DM) is thought to be closely related to arterial stenotic or occlusive disease caused by atherosclerosis. However, there is still no definitive clinical evidence to confirm that patients with diabetes have a higher risk of restenosis.

Objective

This meta-analysis was conducted to determine the effect of DM on restenosis among patients undergoing endovascular treatment, such as percutaneous transluminal angioplasty (PTA) or stenting.

Data sources and study selection

The PubMed/Medline, EMBASE and Cochrane Library electronic databases were searched from 01/1990 to 12/2022, without language restrictions. Trials were included if they satisfied the following eligibility criteria: (1) RCTs of patients with or without DM; (2) lesions confined to the coronary arteries or femoral popliteal artery; (3) endovascular treatment via PTA or stenting; and (4) an outcome of restenosis at the target lesion site. The exclusion criteria included the following: (1) greater than 20% of patients lost to follow-up and (2) a secondary restenosis operation.

Data extraction and synthesis

Two researchers independently screened the titles and abstracts for relevance, obtained full texts of potentially eligible studies, and assessed suitability based on inclusion and exclusion criteria.. Disagreements were resolved through consultation with a third researcher. Treatment effects were measured by relative ratios (RRs) with 95% confidence intervals (CIs) using random effects models. The quality of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria.

Main outcomes and measures

The main observation endpoint was restenosis, including > 50% stenosis at angiography, or TLR of the primary operation lesion during the follow-up period.

Results

A total of 31,066 patients from 20 RCTs were included. Patients with DM had a higher risk of primary restenosis after endovascular treatment (RR = 1.43, 95% CI: 1.25–1.62; p = 0.001).

Conclusions and relevance

This meta-analysis of all currently available RCTs showed that patients with DM are more prone to primary restenosis after endovascular treatment.

Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15:230–40. https://doi.org/10.1038/nrcardio.2017.154.CrossRefPubMed

Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010.CrossRefPubMedPubMedCentral

Gori T. Restenosis after coronary stent implantation: cellular mechanisms and potential of endothelial progenitor cells (A Short Guide for the Interventional Cardiologist). Cells. 2022. https://doi.org/10.3390/cells11132094.CrossRefPubMedPubMedCentral

Kereiakes DJ, Kandzari DE, Zidar JP. Drug-coated balloons for in-stent restenosis. J Am Coll Cardiol. 2020;76:1391–2. https://doi.org/10.1016/j.jacc.2020.06.082.CrossRefPubMed

Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e686–725. https://doi.org/10.1161/CIR.0000000000000470.CrossRefPubMed

Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10:293–302. https://doi.org/10.1038/nrendo.2014.29.CrossRefPubMed

Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary prevention of cardiovascular disease in diabetes mellitus. J Am Coll Cardiol. 2017;70:883–93. https://doi.org/10.1016/j.jacc.2017.07.001.CrossRefPubMedPubMedCentral

Eckel RH, Bornfeldt KE, Goldberg IJ. Cardiovascular disease in diabetes, beyond glucose. Cell Metab. 2021;33:1519–45. https://doi.org/10.1016/j.cmet.2021.07.001.CrossRefPubMedPubMedCentral

Fishman SL, Sonmez H, Basman C, Singh V, Poretsky L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018;24:59. https://doi.org/10.1186/s10020-018-0060-3.CrossRefPubMedPubMedCentral

10.

Henry H. Ruiz1, Ravichandran Ramasamy1, Ann Marie Schmidt1. Advanced Glycation End Products: Building on the Concept of the “Common Soil” in Metabolic Disease. Endocrine Society 2019. doi: https://doi.org/10.1210/endocr/bqz006/5602541

11.

Jankauskas SS, Kansakar U, Varzideh F, et al. Heart failure in diabetes. Metabolism. 2021;125: 154910. https://doi.org/10.1016/j.metabol.2021.154910.CrossRefPubMedPubMedCentral

12.

Shu J, Matarese A, Santulli G. Diabetes, body fat, skeletal muscle, and hypertension: the ominous chiasmus? J Clin Hypertens (Greenwich). 2019;21:239–42. https://doi.org/10.1111/jch.13453.CrossRefPubMed

13.

Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep. 2014;14:453. https://doi.org/10.1007/s11892-013-0453-1.CrossRefPubMedPubMedCentral

14.

Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis. 2018;275:379–81. https://doi.org/10.1016/j.atherosclerosis.2018.05.033.CrossRefPubMedPubMedCentral

15.

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339: b2700. https://doi.org/10.1136/bmj.b2700.CrossRefPubMedPubMedCentral

16.

Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https://doi.org/10.1136/bmj.d5928.CrossRefPubMedPubMedCentral

17.

Miyazaki Y, Suwannasom P, Sotomi Y, et al. Single or dual antiplatelet therapy after PCI. Nat Rev Cardiol. 2017;14:294–303. https://doi.org/10.1038/nrcardio.2017.12.CrossRefPubMed

18.

Mohan J, Yelamanchili VS, Zacharias SK. Acute Coronary Syndrome Catheter Interventions. In. StatPearls. Treasure Island (FL); 2022.

19.

De Luca L, Bonaca MP, Magnani G. Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. Expert Rev Cardiovasc Ther. 2020;18:881–9. https://doi.org/10.1080/14779072.2020.1833719.CrossRefPubMed

20.

Wang J, Jin X, Huang Y, et al. Endovascular stent-induced alterations in host artery mechanical environments and their roles in stent restenosis and late thrombosis. Regen Biomater. 2018;5:177–87. https://doi.org/10.1093/rb/rby006.CrossRefPubMedPubMedCentral

21.

Wilson S, Mone P, Kansakar U, et al. Diabetes and restenosis. Cardiovasc Diabetol. 2022;21:23. https://doi.org/10.1186/s12933-022-01460-5.CrossRefPubMedPubMedCentral

22.

Balakumar P, Maung UK, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacol Res. 2016;113:600–9. https://doi.org/10.1016/j.phrs.2016.09.040.CrossRefPubMed

23.

Barnes JA, Eid MA, Creager MA, Goodney PP. Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40:1808–17. https://doi.org/10.1161/ATVBAHA.120.314595.CrossRefPubMedPubMedCentral

24.

Nestelberger T, Kaiser C, Jeger R. Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications. Expert Opin Drug Deliv. 2020;17:201–11. https://doi.org/10.1080/17425247.2020.1714590.CrossRefPubMed

25.

Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872–8. https://doi.org/10.1161/01.cir.100.18.1872.CrossRefPubMed

26.

Liu MW, Roubin GS, King SB. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374–87. https://doi.org/10.1161/01.cir.79.6.1374.CrossRefPubMed

27.

Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32:584–9. https://doi.org/10.1016/s0735-1097(98)00286-1.CrossRefPubMed

28.

Jonas M, Edelman ER, Groothuis A, et al. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin-resistant and diabetic animals. Circ Res. 2005;97:725–33. https://doi.org/10.1161/01.RES.0000183730.52908.C6.CrossRefPubMed

29.

Panchatcharam M, Miriyala S, Yang F, et al. Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. Int J Biochem Cell Biol. 2010;42:965–74. https://doi.org/10.1016/j.biocel.2010.02.009.CrossRefPubMedPubMedCentral

30.

Zhou Z, Wang K, Penn MS, et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation. 2003;107:2238–43. https://doi.org/10.1161/01.CIR.0000063577.32819.23.CrossRefPubMed

31.

Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2011;9:53–62. https://doi.org/10.1038/nrcardio.2011.132.CrossRefPubMed

32.

Lee MS, David EM, Makkar RR, Wilentz JR. Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system. J Pathol. 2004;203:861–70. https://doi.org/10.1002/path.1598.CrossRefPubMed

33.

Aronson D, Edelman ER. Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord. 2010;11:75–86. https://doi.org/10.1007/s11154-010-9135-3.CrossRefPubMedPubMedCentral

34.

Hibbert B, O’Brien ER. Circulating endothelial progenitor cells and in-stent restenosis: friend, foe, or none of the above? Can J Cardiol. 2014;30:6–7. https://doi.org/10.1016/j.cjca.2013.11.010.CrossRefPubMed

35.

Park KS, Kang SN, Kim DH, et al. Late endothelial progenitor cell-capture stents with CD146 antibody and nanostructure reduce in-stent restenosis and thrombosis. Acta Biomater. 2020;111:91–101. https://doi.org/10.1016/j.actbio.2020.05.011.CrossRefPubMed

36.

Balestrieri ML, Servillo L, Esposito A, et al. Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation. Diabetologia. 2013;56:162–72. https://doi.org/10.1007/s00125-012-2749-0.CrossRefPubMed

37.

Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32:1866–73. https://doi.org/10.1016/s0735-1097(98)00467-7.CrossRefPubMed

38.

Lexis CP, Rahel BM, Meeder JG, Zijlstra F, van der Horst IC. The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus. Cardiovasc Diabetol. 2009;8:41. https://doi.org/10.1186/1475-2840-8-41.CrossRefPubMedPubMedCentral

39.

Liu C, Zhao Q, Zhao Z, et al. Correlation between estimated glucose disposal rate and in-stent restenosis following percutaneous coronary intervention in individuals with non-ST-segment elevation acute coronary syndrome. Front Endocrinol (Lausanne). 2022;13:1033354. https://doi.org/10.3389/fendo.2022.1033354.CrossRefPubMed

40.

Zhu Y, Liu K, Chen M, et al. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents. Cardiovasc Diabetol. 2021;20:137. https://doi.org/10.1186/s12933-021-01332-4.CrossRefPubMedPubMedCentral

41.

Sasso FC, Pafundi PC, Marfella R, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovasc Diabetol. 2019;18:24. https://doi.org/10.1186/s12933-019-0826-0.CrossRefPubMedPubMedCentral

42.

Marfella R, Sasso FC, Siniscalchi M, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. J Clin Endocrinol Metab. 2012;97:2862–71. https://doi.org/10.1210/jc.2012-1364.CrossRefPubMed

43.

Mone P, Gambardella J, Minicucci F, et al. Hyperglycemia Drives Stent Restenosis in STEMI Patients. Diabetes Care. 2021;44:e192–3. https://doi.org/10.2337/dc21-0939.CrossRefPubMedPubMedCentral

44.

Desouza CV, Gerety M, Hamel FG. Neointimal hyperplasia and vascular endothelial growth factor expression are increased in normoglycemic, insulin resistant, obese fatty rats. Atherosclerosis. 2006;184:283–9. https://doi.org/10.1016/j.atherosclerosis.2005.04.015.CrossRefPubMed

45.

Indolfi C, Torella D, Cavuto L, et al. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation. 2001;103:2980–6. https://doi.org/10.1161/01.cir.103.24.2980.CrossRefPubMed

46.

Marfella R, Sardu C, D’Onofrio N, et al. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. BMC Med. 2023;21:71. https://doi.org/10.1186/s12916-023-02781-2.CrossRefPubMedPubMedCentral

47.

Spadaccio C, Patti G, De Marco F, et al. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study). Am J Cardiol. 2013;112:21–6. https://doi.org/10.1016/j.amjcard.2013.02.046.CrossRefPubMed

48.

Basta G, Berti S, Cocci F, et al. Plasma N-epsilon-(carboxymethyl)lysine levels are associated with the extent of vessel injury after coronary arterial stenting. Coron Artery Dis. 2008;19:299–305. https://doi.org/10.1097/MCA.0b013e3282fec058.CrossRefPubMed

49.

Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–79. https://doi.org/10.1161/CIR.0000000000000471.CrossRefPubMed

50.

Zhang Y, Zhang X, Dong Q, et al. Duration of dual antiplatelet therapy after implantation of drug-coated balloon. Front Cardiovasc Med. 2021;8: 762391. https://doi.org/10.3389/fcvm.2021.762391.CrossRefPubMedPubMedCentral

51.

Damazo-Escobedo CA, Vieyra-Herrera G, Martinez-Rios MA, Garcia-Navarrete MG, Silva-Ruz C. Coronary stent and prolonged dual antiplatelet therapy. A longitudinal study. Gac Med Mex. 2022;158:216–21. https://doi.org/10.24875/GMM.M22000677.CrossRefPubMed

52.

Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:219–29. https://doi.org/10.1016/S0140-6736(17)32409-1.CrossRefPubMed

53.

Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382:1994–2004. https://doi.org/10.1056/NEJMoa2000052.CrossRefPubMed

54.

Anand SS, Caron F, Eikelboom JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018;71:2306–15. https://doi.org/10.1016/j.jacc.2018.03.008.CrossRefPubMed

55.

Kerkmeijer LSM, Tijssen RYG, Hofma SH, et al. Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study. Catheter Cardiovasc Interv. 2021;98:713–20. https://doi.org/10.1002/ccd.29329.CrossRefPubMed

56.

Giannini F, Latib A, Jabbour RJ, et al. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients—results from the BELLO (balloon elution and late loss optimization) trial. Cardiovasc Revasc Med. 2017;18:4–9. https://doi.org/10.1016/j.carrev.2016.12.008.CrossRefPubMed

57.

Konigstein M, Ben-Yehuda O, Smits PC, et al. Outcomes among diabetic patients undergoing percutaneous coronary intervention with contemporary drug-eluting stents: analysis from the BIONICS randomized trial. JACC Cardiovasc Interv. 2018;11:2467–76. https://doi.org/10.1016/j.jcin.2018.09.033.CrossRefPubMed

58.

Franzone A, Pilgrim T, Heg D, et al. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. Circ Cardiovasc Interv. 2015. https://doi.org/10.1161/CIRCINTERVENTIONS.114.002319.CrossRefPubMed

59.

Ruiz-Garcia J, Teles R, Rumoroso JR, et al. Comparison between diabetic and non-diabetic patients after successful percutaneous coronary intervention for chronic total occlusions in the drug-eluting stent era. Rev Port Cardiol. 2015;34:263–70. https://doi.org/10.1016/j.repc.2014.10.009.CrossRefPubMed

60.

Kirtane AJ, Patel R, O’Shaughnessy C, et al. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv. 2009;2:967–76. https://doi.org/10.1016/j.jcin.2009.08.008.CrossRefPubMed

61.

Brener SJ, Mehran R, Dressler O, Cristea E, Stone GW. Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). Am J Cardiol. 2012;109:1111–6. https://doi.org/10.1016/j.amjcard.2011.11.046.CrossRefPubMed

62.

Krankenberg H, Zeller T, Ingwersen M, et al. Self-expanding versus balloon-expandable stents for iliac artery occlusive disease: the randomized ICE trial. JACC Cardiovasc Interv. 2017;10:1694–704. https://doi.org/10.1016/j.jcin.2017.05.015.CrossRefPubMed

63.

Abreu Filho LM, Forte AA, Sumita MK, Favarato D, Meireles GC. Influence of metal alloy and the profile of coronary stents in patients with multivessel coronary disease. Clinics (Sao Paulo). 2011;66:985–9. https://doi.org/10.1590/s1807-59322011000600011.CrossRefPubMed

64.

Kufner S, Byrne RA, de Waha A, et al. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. Cardiovasc Revasc Med. 2014;15:69–75. https://doi.org/10.1016/j.carrev.2014.02.001.CrossRefPubMed

65.

Lenz T, Koch T, Joner M, et al. Ten-year clinical outcomes of biodegradable versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus. J Am Heart Assoc. 2021;10: e020165. https://doi.org/10.1161/JAHA.120.020165.CrossRefPubMedPubMedCentral

66.

Koch T, Lenz T, Joner M, et al. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : results of the intracoronary stenting and angiographic results: test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial. Clin Res Cardiol. 2021;110:1586–98. https://doi.org/10.1007/s00392-021-01854-7.CrossRefPubMedPubMedCentral

67.

Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273–8. https://doi.org/10.1161/01.CIR.0000129767.45513.71.CrossRefPubMed

68.

Billinger M, Beutler J, Taghetchian KR, et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J. 2008;29:718–25. https://doi.org/10.1093/eurheartj/ehn021.CrossRefPubMed

69.

Maeng M, Jensen LO, Tilsted HH, et al. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). Am J Cardiol. 2011;108:1232–7. https://doi.org/10.1016/j.amjcard.2011.06.037.CrossRefPubMed

70.

Jensen LO, Thayssen P, Junker A, et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial). Am J Cardiol. 2012;110:1585–91. https://doi.org/10.1016/j.amjcard.2012.07.022.CrossRefPubMed

71.

Gyldenkerne C, Olesen KKW, Jensen LO, et al. Everolimus-eluting versus biolimus-eluting coronary stent implantation in patients with and without diabetes mellitus. Am J Cardiol. 2019;124:671–7. https://doi.org/10.1016/j.amjcard.2019.05.060.CrossRefPubMed

72.

Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1172–9. https://doi.org/10.1016/j.jacc.2004.10.075.CrossRefPubMed

73.

Yee KM, Buller CE, Catellier D, et al. Effect of bare metal stenting on angiographic and clinical outcomes in diabetic and nondiabetic patients undergoing percutaneous coronary intervention of nonacute occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). Catheter Cardiovasc Interv. 2005;66:178–84. https://doi.org/10.1002/ccd.20410.CrossRefPubMed

74.

Jang S-J, Park D-W, Kim W-J, et al. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial. Catheter Cardiovasc Interv. 2013;81:1106–14. https://doi.org/10.1002/ccd.24603.CrossRefPubMed

Title: Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials
Authors: Xiaolei Sun
Cheng Zhang
Yarong Ma
Yanzheng He
Xiaodong Zhang
Jianbo Wu
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Diabetes
Clopidogrel
Published in: Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-024-02201-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Importance

Objective

Data sources and study selection

Data extraction and synthesis

Main outcomes and measures

Results

Conclusions and relevance

Please log in to get access to this content

Other articles of this Issue 1/2024

Association of triglyceride glucose index and triglyceride glucose-body mass index with sudden cardiac arrest in the general population

Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study

Sex differences in the association between insulin resistance and non-fatal myocardial infarction across glycaemic states

Association between the triglyceride-glucose index and in-hospital major adverse cardiovascular events in patients with acute coronary syndrome: results from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome project

Circ_005077 accelerates myocardial lipotoxicity induced by high-fat diet via CyPA/p47PHOX mediated ferroptosis

Defining double diabetes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials